iwCLL 2023 – Lydia Scarfò
Lydia Scarfò describes prophylactic and therapeutic measures against SARS-CoV-2 in patients with CLL, potential risk factors for mortality, seroconversion in response to vaccination and areas of research and unmet need regarding prevention and treatment of COVID-19 infections in patients with CLL and hematologic malignancies in general. Finally, she gives insights into the clinical implications of XPO1 mutations in CLL patients.
Here is the full iwCLL 2023 report.
More posts
Issues in the management of CLL patients from an international point of view
Issues in the management of CLL patients from an international point of view In
CLL treatment in the real world: insights from across the globe
CLL treatment in the real world: insights from across the globe Second- and lat
Overcoming resistance to targeted inhibitors
Overcoming resistance to targeted inhibitors Subclonal mutations on covalent BT
Long-term results and other findings from clinical trials
Long-term results and other findings from clinical trials MURANO: 7-year data and retr
Continuous BTK inhibition and combination regimens: present and future
Continuous BTK inhibition and combination regimens: present and future Agents o
Preface – iwCLL 2023
Preface – iwCLL 2023 © author's own – Kiyomi Mashima MD, PhD, Medical Oncology, CLL C
